A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: August 19, 2009
Last updated: July 7, 2014
Last verified: July 2014

August 19, 2009
July 7, 2014
August 2009
Not Provided
Acute immunologic response [ Time Frame: assessed days 1-14 and weekly during follow-up ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00962871 on ClinicalTrials.gov Archive Site
  • Early kinetics of viral suppression [ Time Frame: assessed days 1-14 and weekly during follow-up ] [ Designated as safety issue: No ]
  • Early changes in viral sequence associated with viral suppression [ Time Frame: assessed days 1, 14, 28 and 42 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both
An Open-label, Randomized Study to Evaluate the Acute Immunologic Responses in Asian Subjects With E Antigen Positive Chronic Hepatitis B Following Initiation of Therapy for Hepatitis B With Pegasys, Nucleoside Analogues, or Both.

This open-label, randomized, parallel-arm study will assess the early immunologi c response in treatment-naïve Asian male patients with chronic hepatitis B after initiation of treatment with Pegasys or tenofovir or Pegasys plus tenofovir. Pa tients will be randomized to one of 4 cohorts to receive either Pegasys (360mcg subcutaneously weekly) or tenofovir (300mg orally daily) or both or no treatment for 2 weeks. After 2 weeks on study treatment, patients may opt to receive stan dard of care treatment with Pegasys. Target sample size is <50.

Not Provided
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Hepatitis B, Chronic
  • Drug: peginterferon alfa-2a [Pegasys]
    360 micrograms sc/week for 2 weeks
  • Drug: tenofovir
    300mg po daily for 2 weeks
  • Active Comparator: 1
    Intervention: Drug: tenofovir
  • Experimental: 2
    • Drug: peginterferon alfa-2a [Pegasys]
    • Drug: tenofovir
  • Experimental: 3
    Intervention: Drug: peginterferon alfa-2a [Pegasys]
  • No Intervention: 4
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2012
Not Provided

Inclusion Criteria:

  • male adults of Southeast and/or East Asian origin, 18-55 years of age
  • HBeAg-positive chronic hepatitis B
  • detectable HBV DNA

Exclusion Criteria:

  • prior antiviral therapy for chronic hepatitis B
  • evidence of bridging fibrosis, cirrhosis or decompensated liver disease
  • positive test at screening for HAV (IgM), HCV, HDV or HIV
  • history or evidence of medical condition associated with chronic liver disease
  • antineoplastic or immunomodulatory treatment </=6 months prior to first dose of study drug
18 Years to 55 Years
Contact information is only displayed when the study is recruiting subjects
United States,   New Zealand,   Singapore,   Taiwan
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP